Skip to main content

Alecnib 150 mg ( Alectinib)

The information provided on this website about Alecnib 150 mg is intended for general educational and informational purposes only. It is not intended to replace professional medical advice, diagnosis, treatment, or guidance from a qualified healthcare professional.

Alecnib is identified on this website as a product containing alectinib, an oral targeted anticancer medicine used for certain patients with ALK-positive non-small cell lung cancer (NSCLC). Alectinib is a prescription medicine that requires appropriate diagnostic assessment, medical supervision, and ongoing monitoring.

Patients should always consult their oncologist, doctor, or pharmacist before starting, changing, or stopping any cancer treatment.

1. General Information Only

The content published on this website is intended to explain general information about alectinib, including its potential uses, mechanism of action, dosage information, administration, possible side effects, precautions, and treatment considerations.

This information is not a personalized treatment recommendation.

Every patient’s medical condition is different. Treatment decisions depend on factors such as:

  • The confirmed cancer diagnosis.
  • ALK molecular testing results.
  • Cancer stage and disease characteristics.
  • Previous cancer treatments.
  • Age and general health.
  • Liver and kidney function.
  • Other medical conditions.
  • Medicines currently being used.
  • Individual response and tolerance to treatment.

Only a qualified healthcare professional can assess these factors and determine whether alectinib is appropriate for an individual patient.

2. No Substitute for Professional Medical Advice

Information on this website should never be used as a substitute for consultation with an oncologist or another qualified healthcare professional.

Patients should not use website content to:

  • Diagnose themselves.
  • Decide independently whether they have ALK-positive cancer.
  • Start alectinib without a prescription.
  • Change the prescribed dosage.
  • Stop treatment without medical advice.
  • Replace recommended laboratory tests or medical examinations.
  • Manage serious side effects without professional assessment.

If you have questions about your diagnosis or treatment, contact your treating healthcare professional.

3. Prescription Medicine Disclaimer

Alectinib is a prescription anticancer medicine intended for selected patients with specific forms of ALK-positive NSCLC.

Its use requires an appropriate clinical assessment and confirmation of the relevant molecular alteration through suitable diagnostic testing.

The medicine should only be used under the supervision of a qualified healthcare professional. Patients must follow their individual prescription and the official product information applicable to the medicine supplied to them.

Do not share prescription medicines with another person, even if they have similar symptoms or the same type of cancer.

4. Dosage and Administration Disclaimer

Any dosage information presented on this website is provided for general educational purposes.

The adult dosage information discussed for the reference product Alecensa in the United States prescribing information should not automatically be treated as the prescribed dosage for every alectinib product or every patient.

The correct dosage depends on the applicable product information, treatment indication, patient characteristics, and clinical judgment.

Patients should:

  • Follow the dose prescribed by their oncologist.
  • Take the medicine according to the applicable product instructions.
  • Follow food and administration requirements.
  • Avoid taking extra doses after a missed dose.
  • Report repeated missed doses or administration difficulties.
  • Never adjust the dosage independently.

If there is any uncertainty about how to take the medicine, consult a pharmacist or prescribing healthcare professional.

5. Product Information and Manufacturer Disclaimer

Alecnib is identified on this website as a product containing alectinib in a stated strength of 150 mg.

The product’s manufacturer, manufacturing location, regulatory authorization, formulation, and distribution details have not been independently established by the information presented on this page.

The presence of a product name or stated strength on this website should not be interpreted as proof of:

  • Manufacturer identity.
  • Product authenticity.
  • Regulatory approval.
  • Manufacturing quality.
  • Pharmaceutical equivalence to another brand.
  • Current availability.
  • Authorization for sale in a particular country.

Patients and healthcare professionals should verify product-specific details through reliable packaging, manufacturer documentation, and applicable regulatory records before use.

6. Medical Accuracy and Information Updates

Medical knowledge, prescribing recommendations, regulatory requirements, and product information may change over time.

Although reasonable care should be taken when preparing educational content, this website does not guarantee that every statement is complete, current, or applicable to every country or clinical situation.

The official prescribing information for a medicine may differ between countries. Treatment indications, warnings, dosage recommendations, and monitoring requirements should therefore be checked against the current information applicable to the specific product and location.

Patients should not rely on an older website article when making decisions about their current treatment.

7. Side Effects and Safety Disclaimer

Alectinib may cause side effects, including potentially serious adverse reactions. The type and severity of these reactions can vary between patients.

Important safety concerns include:

  • Liver injury.
  • Interstitial lung disease or pneumonitis.
  • Slow heart rate or bradycardia.
  • Muscle pain and possible muscle injury.
  • Hemolytic anemia.
  • Kidney-related complications.
  • Other clinically significant adverse reactions.

Patients should report new, persistent, or worsening symptoms to their healthcare professional.

Seek urgent medical attention for severe breathing difficulty, fainting, signs of a serious allergic reaction, or other potentially life-threatening symptoms.

Information about side effects on this website is not a complete list of every possible adverse reaction. Consult the applicable product information and healthcare professional for a full safety assessment.

8. Drug Interactions Disclaimer

Alectinib may interact with other medicines or health products. These interactions can affect treatment safety or the way medicines work.

Patients should tell their healthcare professional about all products they use, including:

  • Prescription medicines.
  • Non-prescription medicines.
  • Vitamins and minerals.
  • Herbal products.
  • Dietary supplements.
  • Other cancer treatments.

Do not start, discontinue, or change another medicine without discussing it with a doctor or pharmacist.

The information on this website is not a substitute for a professional medication review.

9. Pregnancy and Breastfeeding Disclaimer

Alectinib may cause harm to an unborn baby. Patients who are pregnant, planning pregnancy, or who could become pregnant should discuss the risks with their healthcare professional before treatment.

Appropriate pregnancy testing and contraception precautions may be required according to the applicable prescribing information.

Breastfeeding is not recommended during treatment with the reference Alecensa product under its United States prescribing information. Patients should consult their healthcare professional for product-specific advice and the appropriate period of breastfeeding restriction.

This website does not provide individualized reproductive health advice.

10. No Guarantee of Treatment Results

The information presented on this website should not be interpreted as a promise or guarantee of treatment success.

Alectinib may help control ALK-positive NSCLC in eligible patients, but individual responses vary.

Treatment outcomes depend on several factors, including:

  • Tumor characteristics.
  • Molecular test results.
  • Disease stage.
  • Previous treatment.
  • Overall health.
  • Treatment tolerance.
  • Biological response to the medicine.
  • Development of treatment resistance.

No statement on this website guarantees that alectinib will cure cancer, prevent recurrence, eliminate metastases, or produce a specific treatment outcome.

Patients should discuss realistic treatment goals and expectations with their oncologist.

11. Clinical Research and Study Information

Any clinical research or study information presented on this website is intended to provide general background about alectinib.

Clinical trial findings apply to the populations, treatment settings, and study conditions investigated. They do not necessarily predict the outcome for an individual patient.

The results of clinical research should not be interpreted as a guarantee that every patient will experience the same benefits or risks.

Healthcare professionals should use current clinical evidence, approved prescribing information, and individual patient circumstances when making treatment decisions.

12. External Information and Third-Party Content

This website may discuss medicine-related information associated with manufacturers, research organizations, healthcare professionals, or regulatory authorities.

Any such information should be evaluated in its original context and against reliable documentation.

The website does not automatically endorse or verify statements made by third parties. Product claims, manufacturer details, and regulatory information should be independently confirmed before being relied upon.

13. Website Content and Professional Responsibility

The information on this website is not intended to establish a doctor-patient relationship, provide a medical consultation, or replace the responsibilities of a prescribing healthcare professional.

Patients remain responsible for seeking appropriate medical advice and following their prescribed treatment plan.

Healthcare professionals should use their own clinical judgment and applicable professional standards when evaluating information presented here.

14. Limitation of Responsibility

To the extent permitted by applicable law, the website publisher does not guarantee that the educational information presented is complete, error-free, or suitable for every individual medical circumstance.

The website should not be relied upon as the sole basis for decisions involving diagnosis, prescription, medicine selection, dosage, or treatment changes.

Users should verify important medical and product-specific information with qualified healthcare professionals and appropriate official documentation.

Nothing in this disclaimer is intended to exclude or limit any responsibility that cannot legally be excluded or limited under applicable law.

15. Contact a Healthcare Professional

If you have questions about Alecnib, alectinib treatment, possible side effects, or the suitability of the medicine for a particular diagnosis, consult a qualified healthcare professional.

For urgent symptoms or a suspected serious adverse reaction, seek immediate medical assistance rather than waiting for a response through a website.

Patients should keep their prescription, medicine packaging, and relevant medical records available when discussing treatment with their healthcare team.

Important Notice

By using the educational information on this website, visitors should understand that:

  • The content is for general informational purposes only.
  • It does not replace professional medical advice.
  • Alectinib requires a prescription and medical supervision.
  • Dosage must be determined by a qualified healthcare professional.
  • Product-specific details should be independently verified.
  • Treatment results are not guaranteed.
  • Serious or worsening symptoms require appropriate medical attention.
  • Current official prescribing information should be consulted before treatment decisions are made.

Always consult your oncologist or another qualified healthcare professional before starting, changing, or stopping alectinib treatment.